Revised National Tuberculosis Control Programme
OUTLINE OF PRESENTATION

- Introduction
- Burden Of The Disease
- Evolution Of RNTCP
- Goals And Objectives Of RNTCP
- DOTS
- Stop TB Strategy
- Organization
- RNTCP Endorsed TB Diagnostics
- Newer Initiatives
- TB-HIV,
- Pediatric TB & MDR-TB
- National Strategic Plan
Tuberculosis

- An infectious disease caused by bacteria – *Mycobacterium tuberculosis*
- Spreads through air
  - cough and sneeze of a person suffering *sputum positive pulmonary TB*
- Most common site is lungs (pulmonary TB)-80%
- Many risk factors for progression from infection to disease – HIV, DM, Malnutrition, Smoking, alcoholism, indoor air pollution etc
- 1 untreated smear +ve pulmonary TB case can infect 10-15 individuals per year
Burden of the disease
India is the highest TB burden country accounting more than one fifth of the global incidence

Global incidence: 9 million cases
Deaths: 1.5 million
(global TB report 2014)

Global Rank:
Number of TB cases – 1st
Incidence – 17th highest
Estimated Total TB Burden in India

- **Incidence** of TB disease:
  - 2.2 million new TB cases annually;

- **Prevalence** of TB disease: 2.8 million TB cases

- **Deaths**:
  - ~2,70,000 deaths due to TB each year

- **MDR-TB**:
  - in new TB cases ~2.2% and 15% in Re-treatment cases

- **TB/HIV**:
  - 5.6% of TB patients (1,30,000 HIV-infected TB patients/year)

* Source: WHO 2014, Global TB report
Evolution of RNTCP
TB control efforts in India

• 1962 National TB Programme (NTP) launched
• 1992 NTP review - only 30% diagnosed; of these, only 30% completed treatment
• 1993 RNTCP started as a national programme incorporating the “DOTS Strategy”
• 1998 only 2% total population of India has covered
• 1998 Large scale RNTCP expansion began
• 2000 135 million population covered
• 2003 741 million population covered
• Mar 2006 100% population covered
RNTCP – Goal and Objectives

• Goal
  – The goal of TB control Programme is to decrease mortality and morbidity due to TB and cut transmission of infection until TB ceases to be a major public health problem in India.

• Objectives
  – To achieve and maintain a cure rate of at least 85% among new sputum positive TB patients
  – To achieve and maintain a case detection of at least 70% of such cases *(Estimated incidence)*
Directly Observed Treatment, Short-course (DOTS) – Components

- Political commitment
- Diagnosis by microscopy
- Adequate supply of SCC drugs
- Directly observed treatment
- Accountability

Note: Directly Observed Treatment (DOT) is only one of the five components of DOTS strategy.
1. POLITICAL COMMITMENT
Political Commitment

• Political and Administrable commitment for financial support for the diagnosis of EPTB, financial aid.
• Special incentives for promotion of referrals and notification rates
• Strong coordination, advocacy meetings and liaison at State/ District level.
2. Diagnosis by microscopy
Diagnosis of Pulmonary TB

Cough for 2 Weeks or More

2 Sputum smears

1 or 2 Positives

Sputum Positive PTB Anti TB Treatment

2 Negatives

Antibiotics 10-14 days

Cough persists

Repeat 2 Sputum Examination

1 or 2 Positives

Suggestive of TB

Sputum negative PTB Anti TB Treatment

2 Negative

X-ray chest

Negative for TB

Non TB
Quality-assured diagnostic services

- Sputum microscopy is the primary tool for diagnosing and follow up of infectious pulmonary TB cases
  - ~12,688 decentralized designated microscopy centers upgraded in the General Health System
- External Quality Assurance (EQA) system for sputum microscopy supports quality
3. Adequate supply of SCC drugs
# RNTCP Treatment

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New Cat I</strong></td>
<td>New smear-positive; New sputum smear Negative New Extra pulmonary New others</td>
<td>$2 \text{H}_3\text{R}_3\text{Z}_3\text{E}_3 \left/ 4 \text{H}_3\text{R}_3 \right.$</td>
</tr>
<tr>
<td><strong>Previously treated (Cat II)</strong></td>
<td>Smear Positive relapse Smear positive failure Smear positive treatment after default Others</td>
<td>$2 \text{H}_3\text{R}_3\text{Z}_3\text{E}_3\text{S}_3 \left/ 1 \text{H}_3\text{R}_3\text{Z}_3\text{E}_3 \right.$ / ( \left/ 5 \text{H}_3\text{R}_3\text{E}_3 \right.$</td>
</tr>
</tbody>
</table>

All treatment thrice weekly. Cat I and Cat II extended one month if smear+ at end of initial intensive phase.
Quality treatment services

• Quality-assured drugs in patient-wise boxes and *no stock-outs at any District since RNTCP began*
• Adult boxes and Pediatric boxes contains whole course of treatment
• All RNTCP patients treated under direct observation by a accessible, acceptable and accountable DOT provider
  – DOT provider may be health worker or community-based volunteer
• Referral and feedback system for continuity
• All patients initiated on treatment are monitored individually
• Treatment outcomes are reported through cohort analysis
4. Directly observed treatment
Network of nearly 0.4 million DOT providers

Private doctor in Pune
Unani doctor in Jaipur
NGO Worker in Andhra
Homeo doctor in Pune

Quality of DOT ensured predominantly through Supervision by DTOs, MOTCs, STS
5. Accountability
Programme Surveillance System

Peripheral Health Institute (DMC and other PHIs)

Monthly PHI Report

Tuberculosis Unit

Quarterly CF, SC, RT, PM Reports

District TB Centre
Electronic reports)

Additional Feedback

Quarterly Reports
CF, SC, RT, PM

Central TB Division

State TB Cell

System electronic from district level upwards

22
In addition to implementing core DOTS activities, India is implementing almost all the additional components of the Stop TB Strategy-2006.
COMPONENTS OF THE STOP TB STRATEGY

1. PURSUE HIGH-QUALITY DOTS EXPANSION AND ENHANCEMENT
   a. Political commitment with increased and sustained financing
   b. Case detection through quality-assured bacteriology
   c. Standardized treatment with supervision and patient support
   d. An effective drug supply and management system
   e. Monitoring and evaluation system, and impact measurement

2. ADDRESS TB/HIV, MDR-TB AND OTHER CHALLENGES
   - Implement collaborative TB/HIV activities
   - Prevent and control multidrug-resistant TB
   - Address prisoners, refugees and other high-risk groups and special situations

3. CONTRIBUTE TO HEALTH SYSTEM STRENGTHENING
   - Actively participate in efforts to improve system-wide policy, human resources, financing, management, service delivery, and information systems
   - Share innovations that strengthen systems, including the Practical Approach to Lung Health (PAL)
   - Adapt innovations from other fields

4. ENGAGE ALL CARE PROVIDERS
   - Public-Public, and Public-Private Mix (PPM) approaches
   - International Standards for TB Care (ISTC)

5. EMPOWER PEOPLE WITH TB, AND COMMUNITIES
   - Advocacy, communication and social mobilization
   - Community participation in TB care
   - Patients’ Charter for Tuberculosis Care

6. ENABLE AND PROMOTE RESEARCH
   - Programme-based operational research
   - Research to develop new diagnostics, drugs and vaccines

© WHO 2006
Structure of RNTCP at State level

State TB Cell

- STO, Deputy STO
- MO, Accountant,
- IEC Officer, SA, DEO

District TB Centre

- DTO, MO-DTC, LT,
- DEO, Driver

Tuberculosis Unit

- MO-TC
- STS, STLS

Microscopy Centre

- MO, LT

DOT Centre

- DOT Provider – MPW,
- NGO, Comm Vol

Nodal point for TB control

One/ 5 lakh (2.5 lakh in hilly/difficult/tribal area)

One/ lakh (0.5 lakh in hilly/difficult/tribal area)
Training Modules – RNTCP seeks to reach and train each and every health care provider.
RNTCP ENDORSED TB DIAGNOSTICS

1. Smear microscopy for AFB
   a. Sputum smear stained with Z-N staining. or
   b. Florescence stains and examined under direct or indirect microscopy with or without LED.
2. Culture
   a. Solid (LJ Media) or
   b. Liquid media (middle brook) using manual semi automatic or automatic machines e.g., Bactec, MGIT
3. Rapid diagnostic molecular test
   a. Conventional PCR based line probe assay for MTB COMPLEX; or
   b. Real-time PCR based Nucleic Acid Amplification test NAAT for MTB complex e.g., GeneXpert
NEWER INITIATIVES

- RNTCP currently using CB NAAT for the diagnosis of TB and MDR-TB
- in high risk population like HIV positive and pediatric group.
Drug resistance surveillance (DRS) under RNTCP

- Aim of the DRS is to determine the prevalence of anti-mycobacterial resistance, among new sputum smear positive PTB patients and previously treated PTB patients.
- As per the surveys, MDR-TB to be about 2.2% in new case and 15% in retreatment cases.
- Counselling project to enhance treatment adherence among DRTB patients.
In India today, two deaths occur every three minutes from tuberculosis (TB). But these deaths can be prevented. With proper care and treatment, TB patients can be cured and the battle against TB can be won.

Tuberculosis (TB) is an infectious disease caused by a Bacterium, Mycobacterium tuberculosis. It is spread through the air by a person suffering from TB. A single patient can infect 10 or more people in a year.

India has a long and distinguished tradition of research in TB. Studies from the Tuberculosis Research Centre in Chennai and the National Tuberculosis Institute in Bangalore provided key knowledge to improve treatment of TB patients all around the world.

Modern anti-TB treatment can cure virtually all patients. It is, however, very important that treatment be taken for the prescribed duration, which in every case is a minimum of 6 months. Because treatment is of such a long duration and patients feel better after just 1-2 months, and because many TB patients face other problems such as poverty and unemployment, treatment is often interrupted.
Tuberculosis surveillance using Nikshay: (Case Based online software)

<table>
<thead>
<tr>
<th>Category</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB Patients Registered under RNTCP</td>
<td>32,37,354</td>
</tr>
<tr>
<td>Peripheral Health Institutes (PHI) registered</td>
<td>44,001</td>
</tr>
<tr>
<td>Tuberculosis Officials details</td>
<td>2791</td>
</tr>
<tr>
<td>District TB Officers details</td>
<td>696</td>
</tr>
<tr>
<td>State TB Officers details</td>
<td>35</td>
</tr>
<tr>
<td>Contractual Employees details</td>
<td>7734</td>
</tr>
<tr>
<td>Non-RNTCP Health Establishments registered</td>
<td>78,908</td>
</tr>
<tr>
<td>Non-RNTCP Patients registered</td>
<td>1,28,844</td>
</tr>
<tr>
<td>Culture &amp; Drug Resistant Labs Patients</td>
<td>68,024</td>
</tr>
<tr>
<td>registered</td>
<td></td>
</tr>
<tr>
<td>Drug Resistant Tuberculosis Patients</td>
<td>6160</td>
</tr>
</tbody>
</table>

Mobile app for notification

Nikshay received - National E-Governance Award (Gold) from Ministry of IT, Ministry of Administrative reforms, GOI
During 17th National E-Governance Conference
TB-HIV
Diagnosis of TB in HIV+ Persons

- Diagnosis of TB in HIV-infected persons is more difficult
  - More non-TB respiratory disease
  - More smear-negative and extrapulmonary TB
  - X-rays are even less specific

Proportion of patients with pulmonary TB who have positive AFB smears
**TB and HIV**

- HIV-infected persons are at greatly increased risk of TB.

- Without HIV, the lifetime risk of developing TB in TB-infected people is about 10%, compared with at least 50% in HIV-infected, TB-infected people.

- The HIV epidemic could rapidly increase the incidence of TB.
PEDIATRIC TUBERCULOSIS
PEDIATRIC TUBERCULOSIS

- Accounts 6-8 % of all TB cases.
- As per consensus with Indian Academy of Pediatricians, separate algorithms for diagnosis of PTB and EPTB has been issued.
- Pediatric Patient Wise Boxes recommended by expert Committee and Specifications developed by Technical Committee
• For the first time in the world, PWBs are to be introduced for Pediatric patients
• Rifampicin to be made available in tablet form
• Patients grouped in weight bands (6-10, 11-17, 18-25, 26-30 Kg)
• Only two generic boxes to be used across four weight bands
Multidrug resistant Tuberculosis (MDR-TB)
**MDR T B C A S E**

- Confirmed MDR-TB case: An MDR-TB suspect whose sputum culture is positive and whose TB is due to *Mycobacterium tuberculosis* that are resistant *in-vitro* to at least isoniazid and rifampicin (the culture and DST result being from an RNTCP accredited laboratory).

- Patients who are not MDR but have any Rifampicin resistance will also be treated with Cat IV regimen.
### Causes of Inadequate Treatment

<table>
<thead>
<tr>
<th>Providers/Programmes: Inadequate regimens</th>
<th>Drugs: Inadequate supply/quality</th>
<th>Patients: Inadequate drug intake</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Absence of guidelines or inappropriate guidelines</td>
<td>• Non-availability of certain drugs (stock-outs or delivery disruptions)</td>
<td>• Poor adherence (or poor DOT)</td>
</tr>
<tr>
<td>• Non-compliance with guidelines</td>
<td>• Poor quality</td>
<td>• Lack of information</td>
</tr>
<tr>
<td>• Inadequate training of health staff</td>
<td>• Poor storage conditions</td>
<td>• Non-availability of free drugs</td>
</tr>
<tr>
<td>• No monitoring of treatment</td>
<td>• Wrong dosages or combination</td>
<td>• Adverse drug reactions</td>
</tr>
<tr>
<td>• Poorly organized or funded TB control programmes</td>
<td></td>
<td>• Social and economic barriers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Malabsorption</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Substance abuse disorders</td>
</tr>
</tbody>
</table>

Leads to Multi Drug Resistant TB
MDR-TB Suspect can be any of the following:

- Any TB patient who fails an RNTCP Category I treatment regimen;
- Any RNTCP Category II patient who is sputum smear positive at the end of the fourth month of treatment or later; or
- Close contacts of MDR-TB patients who are found to have smear positive pulmonary TB (PTB) disease
RNTCP Response to MDR/XDR-TB

- Prevention of drug resistance through sustained high-quality DOTS implementation
  - Promote rational use of anti-TB drugs in the country
- Improve laboratory capacity to diagnose MDR-TB and monitor treatment
- Effective treatment of MDR-TB patients through implementation of RNTCP DOTS-Plus (Category IV services)
- Evaluate the extent of the threat of second-line anti-TB drug resistance and provide for XDR-TB treatment
**DOTS-Plus strategy**

- Sustained government commitment;
- Accurate, timely diagnosis through quality assured culture and drug susceptibility testing;
- Appropriate treatment utilizing second-line drugs under strict supervision;
- Uninterrupted supply of quality assured anti-TB drugs; and
- Standardized recording and reporting system.
Treatment

RNTCP CATEGORY IV REGIMEN: 6 (9) Km Lvx Eto Cs Z E / 18 Lvx Eto Cs E
NATIONAL STRATEGIC PLAN (2012-2017)

• Objectives:
  – 90/90
    – Detection of at least 90% of all incident TB Cases Including DRTB and HIV associated TB.
    – Successfully treat at least 90% of new smear positive cases and at least 85% of previously treated TB patients
    – Reduction in default rate of new TB cases to less than 5%  retreatment TB cases to less than 10%
– Initial screening of all re-treatment smear positive till 2015 and all smear positive TB by 2017 for DRTB and provision of treatment services for MDRTB patients.

– Extend RNTCP services to patients diagnosed and treated in private sector.
• Targets:
  – Detection and treatment of 87 lakhs tuberculosis patients during the 12th five year plan.
  – Detection and treatment of at least 2 lakh MDRTB patients
  – Reduction in delay in diagnosis and treatment of all types of TB
  – Increase in access to services to marginalized and hard to reach populations, and high risk and vulnerable groups
Achievements of RNTCP

• Covers whole country since 2006
• Treatment success rate has more than trebled from 25% in 1998 to 88% in 2013
• Death rates brought down several folds from 29% to 4%
• More than 16 million patients have been initiated in treatment, saving almost 2.8 million lives.
Fate of Pulmonary TB under different programme conditions

- No Programme
- Poor Programme
- Good Programme

- Black: Die
- Red: Chronic
- Blue: Cure

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Thanks